The Ever Changing Treatments for Tumors of the Central Nervous System

Author(s): Patricia Tai, Osama Souied

Journal Name: Current Cancer Therapy Reviews

Volume 16 , Issue 3 , 2020

Become EABM
Become Reviewer

[1]
Ferlay JS, Bray F. Forman D, Mathers C, Parkin DM Cancer Incidence and Mortality Worldwide: IARC Cancer Base No 10 2008.International Agency for Research on Cancer Lyon, France.
[2]
Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization classification of tumors of the central nervous system: A summary. Acta Neuropathol 2016; 131(6): 803-20.
[3]
AJCC Cancer Staging Manual. 8th ed.; Springer: Switzerland. 2017.
[4]
Stupp R, Mason WP, van den Bent MJ, et al. European Organisation for research and treatment of cancer brain tumor and radiotherapy groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant TMZ for glioblastoma. N Engl J Med 2005; 352(10): 987-96.
[5]
Wolters Kluwer Available from:. www.uptodate.com
[6]
Perry JR, Laperriere N, O’Callaghan CJ, et al. Short-course radiation plus temozolomide in elderly patients with glioblastoma. N Engl J Med 2017; 376(11): 1027-37.
[7]
van den Bent MJ, Baumert B, Erridge SC, et al. Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: A phase 3, randomised, open-label intergroup study. Lancet 2017; 390(10103): 1645-53.
[8]
US National Library of Medicine Radiation therapy with concomitant and adjuvant Temozolomide versus radiation therapy with adjuvant PCV chemotherapy in patients with anaplastic glioma or low grade glioma.Avaialble from: https://clinicaltrials.gov/ct2/show/NCT00887146
[9]
Van Den Bent MJ, Klein M, Smits M, et al. Final results of the EORTC Brain Tumor Group randomized phase II TAVAREC trial on TMZ with or without bevacizumab in 1st recurrence grade II/III glioma without 1p/19q co-deletion. J Clin Oncol 2009; S35: 15.
[10]
Wick W, Gorlia T, Bendszus M, et al. Lomustine and Bevacizumab in progressive glioblastoma. N Engl J Med 2017; 377(20): 1954-63.
[11]
US National Library of Medicine. A study of the effectiveness and safety of Nivolumab compared to Bevacizumab and of Nivolumab with or without Ipilimumab in Glioblastoma patients (CheckMate 143). Available from:. https://clinicaltrials.gov/ct2/show/NCT02017717
[12]
Stupp R, Taillibert S, Kanner AA, et al. Maintenance therapy with tumor-treating fields plus TMZ vs.TMZ alone for glioblastoma. JAMA 2015; 314(23): 2535-9.
[13]
Soffietti R, Baumert BG, Bello L, et al. European Federation of Neurological Societies. Guidelines on management of low-grade gliomas: Report of an EFNS-EANO Task Force. Eur J Neurol 2010; 17(9): 1124-33.
[14]
Rudà R, Reifenberger G, Frappaz D, et al. EANO guidelines for the diagnosis and treatment of ependymal tumors. Neuro-oncol 2018; 20(4): 445-56.
[15]
EORTC. The future of cancer therapy Avaiable from: http://www.eortc.org/research_field/brain/
[16]
European Association of Neuro-Oncology. EANO guidlines Avaiable from: https://www.eano.eu/publications/eano-guidelines/


promotion: free to download

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 16
ISSUE: 3
Year: 2020
Published on: 14 September, 2020
Page: [166 - 167]
Pages: 2
DOI: 10.2174/157339471603200914115813

Article Metrics

PDF: 21
HTML: 2